Retrospective Analysis of Acute Rehabilitation Outcomes of Cancer Inpatients with Leptomeningeal Disease

We assessed the correlations of the Frailty Instrument for primary care of the Survey of Health,Ageing and Retirement in Europe (SHARE-FI on admission: non-frail, pre-frail, frail) with the outcomes of aShort-term Post-Acute Rehabilitative Care programme (N=172 admissions over one-year period, 95 of whichwere frail). SHARE-FI correlated with age (non-frail: mean 79.2 years; frail: 83.6; P<0.001). Adjusting for age,SHARE-FI correlated with longer length of stay (non-frail: median 30 days; frail: 42; P=0.047), higher rate ofemergency transfer to acute hospital (non-frail: 2.4%; frail: 21.1%; P=0.004), and lower home discharge rate(non-frail: 97.6%; frail: 81.9%; P=0.009). While frailty correlated with more disability on admission anddischarge, there was no statistically significant difference in Barthel Index (BI) improvement across frailtycategories (all groups had median BI improvement of ≥2 points, P=0.247). The post-acute rehabilitation of thefrail is worthwhile but requires more time and access to acute hospital facilities.

Download Full-text

Post-Acute Rehabilitation Outcomes After Stroke: A Comparison With Traumatic Brain Injury

Archives of Physical Medicine and Rehabilitation ◽

10.1016/j.apmr.2017.09.058 ◽

2017 ◽

Vol 98 (12) ◽

pp. e167

Author(s):

Keira O'Dell ◽

Katy Mitchell ◽

Layla Rodriguez ◽

Matthew Ruhe ◽

Jill Seale ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Rehabilitation Outcomes ◽

Acute Rehabilitation

Download Full-text

Poster 17: Traumatic Brain Injury Medical Severity Models: Predicting Acute Rehabilitation Outcomes

Archives of Physical Medicine and Rehabilitation ◽

10.1016/j.apmr.2008.09.042 ◽

2008 ◽

Vol 89 (11) ◽

pp. e25

Author(s):

Ronald Seel ◽

Darryl L. Kaelin ◽

Stephen Macciocchi

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Rehabilitation Outcomes ◽

Acute Rehabilitation ◽

Medical Severity

Download Full-text

The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes

Brain Injury ◽

10.1080/02699050310001646224 ◽

2004 ◽

Vol 18 (8) ◽

pp. 739-750 ◽

Cited By ~ 35

Author(s):

W. Walker ◽

R. Seel ◽

M. Gibellato ◽

H. Lew ◽

M. Cornis-Pop ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Rehabilitation Outcomes ◽

Acute Rehabilitation

Download Full-text

NIMG-10. A RETROSPECTIVE ANALYSIS OF SURVIVAL FOLLOWING TREATMENT WITH BEVACIZUMAB IN GLIOBLASTOMA PATIENTS WITH RADIOGRAPHICALLY-CONFIRMED SUBEPENDYMAL OR LEPTOMENINGEAL SPREAD OF DISEASE

Neuro-Oncology ◽

10.1093/neuonc/noaa215.623 ◽

2020 ◽

Vol 22 (Supplement_2) ◽

pp. ii148-ii149

Author(s):

Shama Farooq ◽

Onur Yildirim ◽

Robert Young ◽

Jamie Tisnado ◽

Alexandra Miller

Keyword(s):

Retrospective Analysis ◽

Leptomeningeal Disease ◽

Stage Disease ◽

Significant Difference ◽

Mri Scans ◽

Group 3 ◽

Group 2 ◽

Parenchymal Disease ◽

Disseminated Disease ◽

Group 1

Abstract OBJECTIVE We performed a retrospective analysis examining subependymal disease (SED) and leptomeningeal disease (LMD) in bevacizumab treated IDH-wildtype glioblastoma (GBM) patients to assess potential differences in survival. BACKGROUND GBMs are highly infiltrative and often invade the subependymal and leptomeningeal space making them challenging to treat. At recurrence, patients are commonly treated with bevacizumab, which leads to decreased tumor size and swelling. Patients have improved PFS, but there is no benefit in OS. This may reflect infiltrative disease progression--a hallmark of late-stage disease. We hypothesized patients with CSF spread manifested by SED and LMD may have worse outcomes after bevacizumab than patients with non-disseminated disease. METHODS We retrospectively reviewed charts of all IDH-wildtype GBM patients who received bevacizumab in 2016. MRI scans were reviewed by experienced neuro-radiologists to characterize patients into radiographically defined groups (“0” = no LMD/no SED; “1”= no SED/LMD contact; “2”= no SED/LMD dissemination, and “3’= LMD present). Survival from initiation of bevacizumab to death for each group was compared to group “0” (with no SED/LMD). Survival outcomes were analyzed via t-tests. RESULTS We evaluated 87 IDH-WT GBM patients. Radiographically, patients were grouped-- “0”= 16 (18%), “1”= 33 (38%), “2”= 20 (23%), and “3”= 18 (21%). There was no difference between group “0” and any radiographically defined subgroups. Median survival for group “0”= 187 days; group “1”= 219 days; group “2”= 217 days; group “3”= 169 days. CONCLUSION Contrary to our hypothesis, there was no significant difference in survival from the initiation of bevacizumab in patients with SED or LMD. This may be related to the fact that these patients also typically have a high burden of parenchymal disease. Further work is necessary to test this hypothesis in a larger cohort.

Download Full-text